These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17157390)

  • 1. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
    Papakostas GI; Petersen T; Sklarsky KG; Nierenberg AA; Alpert JE; Fava M
    Psychiatry Res; 2007 Jan; 149(1-3):195-200. PubMed ID: 17157390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine.
    Papakostas GI; Crawford CM; Scalia MJ; Fava M
    Neuropsychobiology; 2007; 56(2-3):132-7. PubMed ID: 18259086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
    Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine.
    Denninger JW; Papakostas GI; Mahal Y; Merens W; Alpert JE; Nierenberg AA; Yeung A; Fava M
    Psychosomatics; 2006; 47(4):348-52. PubMed ID: 16844895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen TJ; Iosifescu DV; Summergrad P; Sklarsky KG; Alpert JE; Nierenberg AA; Fava M
    J Clin Psychiatry; 2004 Apr; 65(4):543-6. PubMed ID: 15119918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    Ninan PT; Hassman HA; Glass SJ; McManus FC
    J Clin Psychiatry; 2004 Mar; 65(3):414-20. PubMed ID: 15096082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder.
    Dording CM; Sinicropi-Yao L; Papakostas G; Matthews JD; Nierenberg AA; Fava M; Mischoulon D
    Nord J Psychiatry; 2009; 63(5):420-5. PubMed ID: 19521922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder.
    Shahsavand-Ananloo E; Berenji F; Sadeghniiat K; Alimadadi A; Zahiroddin AR; Tabatabaee M; Abbasi-Asl M; Ghaeli P
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1155-61. PubMed ID: 23690183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
    Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
    Papakostas GI; Petersen T; Hughes ME; Nierenberg AA; Alpert JE; Fava M
    Psychiatry Res; 2004 May; 126(3):287-90. PubMed ID: 15157754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
    Joliat MJ; Schmidt ME; Fava M; Zhang S; Michelson D; Trapp NJ; Miner CM
    J Clin Psychiatry; 2004 Mar; 65(3):373-8. PubMed ID: 15096077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment.
    Iosifescu DV; Nierenberg AA; Alpert JE; Papakostas GI; Perlis RH; Sonawalla S; Fava M
    Psychosomatics; 2004; 45(5):419-25. PubMed ID: 15345787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study.
    Salminen JK; Karlsson H; Hietala J; Kajander J; Aalto S; Markkula J; Rasi-Hakala H; Toikka T
    Psychother Psychosom; 2008; 77(6):351-7. PubMed ID: 18701831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
    Cao Y; Li W; Shen J; Malison RT; Zhang Y; Luo X
    Asia Pac Psychiatry; 2013 Dec; 5(4):276-83. PubMed ID: 23857826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.